2021
-
Novel RET Inhibitors Promising in Chinese Patients with RET-fusion Positive NSCLC
The results of two studies presented at the 2021 World Conference on Lung Cancer—LIBRETTO-321 and ARROW—indicate that the selective RET inhibitors selpercatinib and pralsetinib are promising treatment options for patients […]
-
Second-Line Platinum-Doublet Regimens Reasonable in SCLC
Use of platinum-doublet chemotherapy regimen as second-line treatment for patients with relapsed small-cell lung cancer (SCLC) was a reasonable option compared with nonplatinum-based regimens, according to data from a meta-analysis […]
-
Multifaceted Initiative Launches Aimed at Reducing Lung Cancer Deaths 25% by 2030
The Baptist Cancer Center in Memphis, Tennessee, has launched a new initiative that comprises seven components that will address prevention, diagnosis, and treatment of lung cancer through smoking cessation, low-dose […]
-
Increasing Adherence to CT Lung Cancer Screening Programs
Two large-scale, randomized controlled trials—the U.S. National Lung Screening Trial (NLST; n = 53,454) and the Dutch–Belgian Randomized Lung Cancer Screening Trial (NELSON; n = 15,792)—have demonstrated that lung cancer […]
-
COVID-19 and Lung Cancer
Data from multiple groups1,2 have shown the significant impact of COVID-19 infection among patients with malignancies, leading to high overall morbidity and mortality; this includes our own institution,3 which saw […]
-
Determining Adjuvant Therapy Through Recurrence Prediction: New Investigations
Amid growing interest in validating relapse-prediction models, team links high-grade histology, even if not predominant, with worse outcomes in EGFR-mutated stage 1 NSCLC.
-
Psychosocial Needs Remain Largely Unmet for Patients with Lung Cancer, Caregivers
There is a critical need for psychosocial services in the lung cancer care pathway, according to a presentation by Anne-Marie Baird, BS, PhD, on behalf of Lung Cancer Europe (LUCE), […]
-
Advocacy for Patients With Lung Cancer: Getting Involved at the Government Level in the United States
Every meeting begins with sharing your story. In summary, this is mine: My name is Liz, and I’m one of your constituents. I was diagnosed with lung cancer 15 years […]
-
Pembrolizumab Plus Platinum-Doublet Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Unresectable, Locally Advanced Stage III NSCLC: The KEYNOTE-799 Trial in Perspective
Approximately one-third of patients with NSCLC are diagnosed with unresectable, locally advanced (LA) stage III disease.1 Historically, the standard of care for these patients has been concurrent platinum-based chemotherapy with […]
-
The Evolution of Palliative Care for Metastatic Lung Cancer
In August 2010, Dr. Jennifer Temel and her colleagues1 reported in the New England Journal of Medicine that patients who received early palliative care integrated with standard oncologic care from […]
View ILCN Archives
Provider Resources